Medivation Inc (NASDAQ:MDVN) Rating Reconfirmed
Medivation Inc (NASDAQ:MDVN) had its stock rating noted as “Sector Perform” by analysts at RBC Capital Markets. This was revealed to investors in analysts report on Monday, 28 September.
NASDAQ:MDVN is now trading -4.37% lower at $39.82 as of 14:51 New York time. Medivation Inc’s stock is down -62.41% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has decreased -6.24% over the same time period.
Out of 15 brokers covering Medivation Inc, 12 rate it a Buy, 5 indicate a Hold while 1 suggest a Sell. The highest target is $90 and the lowest is $40 according to Thomson/First Call. The 12-month mean target is $68.03, which means upside potential of 70.84% over the current price.
Institutional Ownership
Knoll Capital Management Lp had the biggest stake with ownership of 2.20M shares as of q2 2015 for 80.96% of the US equity exposure. Selkirk Management Llc is another quite bullish fund who is possessing 64,300 shares of Medivation Inc or 4.03% of their US equity exposure. Further, Healthcor Management L.P. have 4.02% of their US equity exposure invested in the company for 700,000 shares. The Switzerland-based fund Bb Biotech Ag revealed it had bought so far a stake worth about 4% of the fund’s stock portfolio in Medivation Inc. The New York-based fund Opus Point Partners Management Llc is also positive about the stock, possessing 1.29M shares or 3.11% of their US equity exposure.
Insider Activity
Over the last six months, Medivation Inc NASDAQ:MDVN has seen 0 insider purchases, and 8 insider sales. The net result was for 8 transactions, worth $6.50 million.
Medivation Inc (NASDAQ:MDVN) Profile
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).
Medivation Inc (NASDAQ:MDVN) traded down -4.37% on 28 September, hitting $39.82. A total of 2.67 million shares of the company’s stock traded hands. This is up from average of 2.17M shares. Medivation Inc has a 52 week low of $38.98 and a 52 week high of $70.79. The company has a market cap of $6.82 billion and a P/E ratio of 25.35.
